studyhammers

65 results found.

Top Stocks matching your search for "study hammers"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
JSPR

Jasper Therapeutics Inc

3.78%

$1.85 - $1.92

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 5, 2023

It’s up 20% today and still at $0.60 pps Phase 3 p... See more

Jan, 4, 2023

$JSPR PHASE 2 SUCCESSFULLY COMPLETED AT $ENSC 🚀 🚀 ! !

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
IBRX

ImmunityBio Inc

-57.41%

$4.32 - $1.84

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 19, 2023

There is minimal "clinical" risk on the ... See more

Mar, 15, 2023

though much more expensive than chemical entities,... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
TCBP

TC BioPharm Holdings Ltd

-46.03%

$5.67 - $3.06

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 9, 2023

They are extremely confident and hired people to e... See more

Mar, 6, 2023

but future is proving bright here via trials going... See more

JSPR

Jasper Therapeutics Inc

3.78%

$1.85 - $1.92

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 5, 2023

It’s up 20% today and still at $0.60 pps Phase 3 pipeline results in a few weeks

Jan, 4, 2023

$JSPR PHASE 2 SUCCESSFULLY COMPLETED AT $ENSC 🚀 🚀 ! !

Jan, 4, 2023

The study met the primary endpoint of safety and tolerability.

IBRX

ImmunityBio Inc

-57.41%

$4.32 - $1.84

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 19, 2023

There is minimal "clinical" risk on the BLA; it fulfilled all the endpoints with flying colors and looks safe.

Mar, 15, 2023

though much more expensive than chemical entities, are generally considered by health care providers and payers to be worth their cost — as long as the appropriate patients receive them and achieve the desired clinical outcomes.

Mar, 6, 2023

Dilution and CEO July trial is no bueno here 🤗 Puts look wonderful

Mar, 6, 2023

If you believe in the science and current studies than buying down here is an amazing opportunity that will deliver in time.

Mar, 4, 2023

Overall well-being health-related quality of life scores for patients treated with omidubicel showed clinical benefit compared to standard of care, the company said.”

Feb, 7, 2023

but with IBRX current pipeline, peer studies confirming the science, and pending PDUFA for N-803 + BCG I remain bullish.

Dec, 27, 2022

People who received the trial treatment lived with improved quality and longer.

Nov, 29, 2022

6) Good possibility of FDA approving our pancreatic cocktail for phase 3 (I think?).

Nov, 22, 2022

because the trial results show that lives are improved.

TCBP

TC BioPharm Holdings Ltd

-46.03%

$5.67 - $3.06

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 9, 2023

They are extremely confident and hired people to enter the big market of the USA , they have not stopped other trials they are in !!!!

Mar, 6, 2023

but future is proving bright here via trials going into phase 2, old news here… let’s stay optimistic here, enjoy the ride. 🍻🍻

Feb, 13, 2023

$TCBP sell now and miss huge news of phase 2b/3 results of 5 patients.. which will definitely be GREAT

Feb, 11, 2023

Clinical trials have already shown incredible results and a full trial with 37 patients in ACHIEVE kicks off very soon.

Feb, 5, 2023

main man owns 30 percent and he made a billion on moderna so we have s ’ pedegree’ this one should double or triple easily on good phase III!

Feb, 3, 2023

Successful 2b/3 trial for cancer drug.

Jan, 31, 2023

$TCBP they are in Phase 2/3.. everything is promising for the new drug it seems

Jan, 28, 2023

Read the results from earlier studies. Astounding!!

Jan, 26, 2023

Fast tracked, phase 3.